trumenba suspension for injection in single-dose pre-filled syringe 0.5ml
pfizer private limited - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein - injection, suspension - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein 0.06 mg/0.5ml; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein 0.06 mg/0.5ml
soliris concentrate for solution for infusion 300mgvial
astrazeneca singapore pte ltd - eculizumab - infusion, solution concentrate - 300 mg / vial - eculizumab 300 mg / vial
soliris 300mg30ml concentrate for solution for infusion vials
alexion pharma uk ltd - eculizumab - solution for infusion - 10mg/1ml
epysqli
samsung bioepis nl b.v. - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh).evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
menitorix powder and solvent for solution for injection. haemophilus type b and meningococcal group c conjugate vaccine
glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated
neisvac-c, 0.5 ml. suspension for injection in pre-filled syringe. meningococcal group c polysaccharide conjugate vaccine adsorbed
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - neisseria meningitidis, polysaccharide group, tetanus toxoid - suspension for injection - neisseria meningitidis polysaccharide group c tetanus toxoid - vaccines
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen
menveo meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.
bexsero
glaxosmithkline australia pty ltd - neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; histidine; sodium chloride; sucrose - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.
bexsero
glaxosmithkline australia pty ltd - neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram - injection, suspension - excipient ingredients: sucrose; histidine; water for injections; aluminium hydroxide hydrate; sodium chloride - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.